Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

A recent genetic study has provided new insights into how glucagon-like peptide-1 (GLP-1) receptor agonists aid weight loss.

In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...

(HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Participants Patients with type 2 diabetes. Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 ...